{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:24:01Z","timestamp":1761060241468},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"DOI":"10.13039\/501100001809","name":"NSFC","doi-asserted-by":"crossref","award":["81272451\/H1609","81472762\/H1609","81670154\/H0812","81470355\/H1616","81100378\/H0812"],"award-info":[{"award-number":["81272451\/H1609","81472762\/H1609","81670154\/H0812","81470355\/H1616","81100378\/H0812"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"National High Technology Research and Development Program of China","award":["2006AA02Z4B5"],"award-info":[{"award-number":["2006AA02Z4B5"]}]},{"name":"MOE","award":["20134423110002"],"award-info":[{"award-number":["20134423110002"]}]},{"name":"Foundation of Bureau of Education of Guangzhou Municipality","award":["1201410214"],"award-info":[{"award-number":["1201410214"]}]},{"name":"GD-NSF","award":["2014A030313492"],"award-info":[{"award-number":["2014A030313492"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s13045-016-0359-x","type":"journal-article","created":{"date-parts":[[2016,11,25]],"date-time":"2016-11-25T00:51:14Z","timestamp":1480035074000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Nickel pyrithione induces apoptosis in chronic myeloid leukemia cells resistant to imatinib via both Bcr\/Abl-dependent and Bcr\/Abl-independent mechanisms"],"prefix":"10.1186","volume":"9","author":[{"given":"Xiaoying","family":"Lan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peiquan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Zang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinjie","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinghong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huidan","family":"Long","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongbiao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bing Z.","family":"Carter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuejun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xianping","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinbao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,11,25]]},"reference":[{"issue":"4","key":"359_CR1","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1038\/sj.leu.2402879","volume":"17","author":"CA Schiffer","year":"2003","unstructured":"Schiffer CA, Hehlmann R, Larson R. Perspectives on the treatment of chronic phase and advanced phase CML and Philadelphia chromosome positive ALL(1). Leukemia. 2003;17(4):691\u20139.","journal-title":"Leukemia"},{"issue":"13","key":"359_CR2","doi-asserted-by":"crossref","first-page":"4808","DOI":"10.1182\/blood-2008-07-077958","volume":"112","author":"BJ Druker","year":"2008","unstructured":"Druker BJ. Translation of the Philadelphia chromosome into therapy for CML. Blood. 2008;112(13):4808\u201317.","journal-title":"Blood"},{"issue":"6","key":"359_CR3","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/nrc2147","volume":"7","author":"BDJ MeloJV","year":"2007","unstructured":"MeloJV BDJ. Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat Rev Cancer. 2007;7(6):441\u201353.","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"359_CR4","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/leu.2010.257","volume":"25","author":"H Modi","year":"2011","unstructured":"Modi H, Li L, Chu S, Rossi J, Yee JK, Bhatia R. Inhibition of Grb2 expression demonstrates an important role in BCR-ABL-mediatedMAPK activation and transformation of primary human hematopoietic cells. Leukemia. 2011;25(2):305\u201312.","journal-title":"Leukemia"},{"issue":"50","key":"359_CR5","doi-asserted-by":"crossref","first-page":"39223","DOI":"10.1074\/jbc.M007291200","volume":"275","author":"F Gesbert","year":"2000","unstructured":"Gesbert F, Sellers WR, Signoretti S, Loda M, Griffin JD. BCR\/ABL regulates expression of the cyclin-dependent kinase inhibitor p27Kip1 through the phosphatidylinositol 3-Kinase\/AKT pathway. J Biol Chem. 2000;275(50):39223\u201330.","journal-title":"J Biol Chem"},{"issue":"21","key":"359_CR6","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1038\/sj.onc.1203484","volume":"19","author":"RP DanialNN","year":"2000","unstructured":"DanialNN RP. JAK-STAT signaling activated by Abl oncogenes. Oncogene. 2000;19(21):2523\u201331.","journal-title":"Oncogene"},{"issue":"11","key":"359_CR7","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1038\/sj.onc.1201664","volume":"16","author":"MGAJ Amarante-MendesGP","year":"1998","unstructured":"Amarante-MendesGP MGAJ, Nishioka WK, Afar DE, Witte ON, Green DR. Bcl-2-independent Bcr-Abl-mediated resistance to apoptosis: protection is correlated with up regulation of Bcl-xL. Oncogene. 1998;16(11):1383\u201390.","journal-title":"Oncogene"},{"issue":"7","key":"359_CR8","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1038\/leu.2012.19","volume":"26","author":"AR Soliera","year":"2012","unstructured":"Soliera AR, Mariani SA, Audia A, Lidonnici MR, Addya S, Ferrari-Amorotti G, et al. Gfi-1 inhibits proliferation and colony formation of p210BCR\/ABL-expressing cells via transcriptional repression of STAT 5 and Mcl-1. Leukemia. 2012;26(7):1555\u201363.","journal-title":"Leukemia"},{"issue":"5","key":"359_CR9","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.exphem.2012.01.004","volume":"40","author":"K Airiau","year":"2012","unstructured":"Airiau K, Mahon FX, Josselin M, Jeanneteau M, Turcq B, Belloc F. ABT-737 increases tyrosine kinase inhibitor-induced apoptosis in chronic myeloid leukemia cells through XIAP downregulation and sensitizes CD34(+) CD38(-) population to imatinib. Exp Hematol. 2012;40(5):367\u201378.","journal-title":"Exp Hematol"},{"issue":"8","key":"359_CR10","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1182\/blood-2008-03-144790","volume":"113","author":"CJ Quintas-CardamaA","year":"2009","unstructured":"Quintas-CardamaA CJ. Molecular biology of bcr-abl1-positive chronic myeloid leukemia. Blood. 2009;113(8):1619\u201330.","journal-title":"Blood"},{"issue":"10","key":"359_CR11","doi-asserted-by":"crossref","first-page":"3530","DOI":"10.1182\/blood.V99.10.3530","volume":"99","author":"CL Sawyers","year":"2002","unstructured":"Sawyers CL, Hochhaus A, Feldman E, Goldman JM, Miller CB, Ottmann OG, et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood. 2002;99(10):3530\u20139.","journal-title":"Blood"},{"issue":"6","key":"359_CR12","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1182\/blood.V99.6.1928","volume":"99","author":"M Talpaz","year":"2002","unstructured":"Talpaz M, Silver RT, Druker BJ, Goldman JM, Gambacorti-Passerini C, Guihot F, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood. 2002;99(6):1928\u201337.","journal-title":"Blood"},{"issue":"12","key":"359_CR13","doi-asserted-by":"crossref","first-page":"913","DOI":"10.7326\/0003-4819-145-12-200612190-00008","volume":"145","author":"HM Kantarjian","year":"2006","unstructured":"Kantarjian HM, Talpaz M, Giles F, O\u2019Brien S, Cortes J. New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance. Ann Intern Med. 2006;145(12):913\u201323.","journal-title":"Ann Intern Med"},{"key":"359_CR14","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ddtec.2014.03.003","volume":"11","author":"S Balabanov","year":"2014","unstructured":"Balabanov S, Braig M, Brummendorf TH. Current aspects in resistance against tyrosine kinase inhibitors in chronic myelogenous leukemia. Drug Discov Today Technol. 2014;11:89\u201399.","journal-title":"Drug Discov Today Technol"},{"issue":"5","key":"359_CR15","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/j.1600-0609.2011.01689.x","volume":"87","author":"GK VaidyaS","year":"2011","unstructured":"VaidyaS GK, Vundinti BR. Recent developments in drug resistance mechanism in chronic myeloid leukemia: a review. Eur J Haematol. 2011;87(5):381\u201393.","journal-title":"Eur J Haematol"},{"issue":"11","key":"359_CR16","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/S1470-2045(07)70342-X","volume":"8","author":"JF Apperley","year":"2007","unstructured":"Apperley JF. Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol. 2007;8(11):1018\u201329.","journal-title":"Lancet Oncol"},{"issue":"7","key":"359_CR17","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1182\/blood-2007-03-066936","volume":"110","author":"ECA O\u2019HareT","year":"2007","unstructured":"O\u2019HareT ECA, Deininger MW. Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood. 2007;110(7):2242\u20139.","journal-title":"Blood"},{"key":"359_CR18","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/1476-4598-6-67","volume":"6","author":"P Kaur","year":"2007","unstructured":"Kaur P, Feldhahn N, Zhang B, Trageser D, Muschen M, Pertz V, et al. Nilotinib treatment in mouse models of P190 Bcr\/Abl lymphoblastic leukemia. Mol Cancer. 2007;6:67.","journal-title":"Mol Cancer"},{"issue":"24","key":"359_CR19","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa055229","volume":"354","author":"M Talpaz","year":"2006","unstructured":"Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med. 2006;354(24):2531\u201341.","journal-title":"N Engl J Med"},{"issue":"11","key":"359_CR20","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1002\/ijc.23435","volume":"122","author":"K Morinaga","year":"2008","unstructured":"Morinaga K, Yamauchi T, Kimura S, Maekawa T, Ueda T. Overcoming imatinib resistance using Src inhibitor CGP76030, Abl inhibitor nilotinib and Abl\/Lyn inhibitor INNO-406 in newly established K562 variants with BCR-ABL gene amplification. Int J Cancer. 2008;122(11):2621\u20137.","journal-title":"Int J Cancer"},{"key":"359_CR21","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.ccr.2014.07.006","volume":"26","author":"MS Zabriskie","year":"2014","unstructured":"Zabriskie MS, Eide CA, Tantravahi SK, Vellore NA, Estrada J, Nicolini FE, et al. BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia. Cancer Cell. 2014;26:428\u201342.","journal-title":"Cancer Cell"},{"issue":"19","key":"359_CR22","doi-asserted-by":"crossref","first-page":"5250","DOI":"10.1182\/blood-2011-05-349191","volume":"118","author":"T O\u2019Hare","year":"2011","unstructured":"O\u2019Hare T, Zabriskie MS, Eide CA, Agarwal A, Adrian LT, You H, et al. The BCR-ABL35INS insertion\/truncation mutant is kinase-inactive and does not contribute to tyrosine kinase inhibitor resistance in chronic myeloid leukemia. Blood. 2011;118(19):5250\u20134.","journal-title":"Blood"},{"issue":"1","key":"359_CR23","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jinorgbio.2011.09.003","volume":"106","author":"CN Verani","year":"2012","unstructured":"Verani CN. Metal complexes as inhibitors of the 26S proteasome in tumor cells. J Inorg Biochem. 2012;106(1):59\u201367.","journal-title":"J Inorg Biochem"},{"issue":"1","key":"359_CR24","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.taap.2008.03.009","volume":"231","author":"V Milacic","year":"2008","unstructured":"Milacic V, Chen D, Giovagnini L, Diez A, Fregona D, Dou QP. Pyrrolidine dithiocarbamate-zinc(II) and -copper(II) complexes induce apoptosis in tumor cells by inhibiting the proteasomal activity. Toxicol Appl Pharmacol. 2008;231(1):24\u201333.","journal-title":"Toxicol Appl Pharmacol"},{"key":"359_CR25","doi-asserted-by":"crossref","first-page":"5240","DOI":"10.1038\/srep05240","volume":"4","author":"N Liu","year":"2014","unstructured":"Liu N, Liu C, Li X, Liao S, Song W, Yang C, et al. A novel proteasome inhibitor suppresses tumor growth via targeting both 19S proteasome deubiquitinases and 20S proteolytic peptidases. Sci Rep. 2014;4:5240.","journal-title":"Sci Rep"},{"issue":"30","key":"359_CR26","doi-asserted-by":"crossref","first-page":"3536","DOI":"10.1038\/onc.2011.521","volume":"31","author":"M Tailler","year":"2012","unstructured":"Tailler M, Senovilla L, Lainey E, Thepot S, Metivier D, Sebert M, et al. Antineoplastic activity of ouabain and pyrithione zinc in acute myeloid leukemia. Oncogene. 2012;31(30):3536\u201346.","journal-title":"Oncogene"},{"key":"359_CR27","doi-asserted-by":"publisher","first-page":"5916","DOI":"10.1038\/onc.2016.114","volume":"35","author":"C Zhao","year":"2016","unstructured":"Zhao C, Chen X, Zang D, Lan X, Liao S, Yang C, et al. A novel nickel complex works as a proteasomal deubiquitinase inhibitor for cancer therapy. Oncogene. 2016;35:5916\u201327. doi: 10.1038\/onc.2016.114 .","journal-title":"Oncogene"},{"issue":"11","key":"359_CR28","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1182\/blood-2008-06-164582","volume":"115","author":"NB Heaney","year":"2010","unstructured":"Heaney NB, Pellicano F, Zhang B, Crawford L, Chu S, Kazmi SM, et al. Bortezomib induces apoptosis in primitive chronic myeloid leukemia cells including LTC-IC and NOD\/SCID repopulating cells. Blood. 2010;115(11):2241\u201350.","journal-title":"Blood"},{"issue":"1","key":"359_CR29","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1158\/1078-0432.CCR-13-1063","volume":"20","author":"X Shi","year":"2014","unstructured":"Shi X, Chen X, Li X, Lan X, Zhao C, Liu S, et al. Gambogic acid induces apoptosis in imatinib-resistant chronic myeloid leukemia cells via inducing proteasome inhibition and caspase-dependent Bcr-Abl downregulation. Clin Cancer Res. 2014;20(1):151\u201363.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"359_CR30","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1158\/1078-0432.CCR-08-2141","volume":"15","author":"X Shi","year":"2009","unstructured":"Shi X, Jin Y, Cheng C, Zhang H, Zou W, Zheng Q, et al. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation. Clin Cancer Res. 2009;15(5):1686\u201397.","journal-title":"Clin Cancer Res"},{"issue":"9","key":"359_CR31","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1158\/1535-7163.MCT-09-0386","volume":"8","author":"DH Mak","year":"2009","unstructured":"Mak DH, Schober WD, Chen W, Konopleva M, Cortes J, Kantarjian HM, et al. Triptolide induces cell death independent of cellular responses to imatinib in blast crisis chronic myelogenous leukemia cells including quiescent CD34+ primitive progenitor cells. Mol Cancer Ther. 2009;8(9):2509\u201316.","journal-title":"Mol Cancer Ther"},{"key":"359_CR32","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1182\/asheducation-2008.1.427","volume":"1","author":"JV Melo","year":"2008","unstructured":"Melo JV, Chuah C. Novel agents in CML therapy: tyrosine kinase inhibitors and beyond. Hematology Am Soc Hematol Educ Program. 2008;1:427\u201335.","journal-title":"Hematology Am Soc Hematol Educ Program."},{"issue":"4","key":"359_CR33","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1182\/blood-2004-12-4704","volume":"107","author":"BZ Carter","year":"2006","unstructured":"Carter BZ, Mak DH, Schober WD, Cabreira-Hansen M, Beran M, McQueen T, et al. Regulation of survivin expression through Bcr-Abl\/MAPK cascade: targeting survivin overcomes imatinib resistance and increases imatinib sensitivity in imatinib-responsive CML cells. Blood. 2006;107(4):1555\u201363.","journal-title":"Blood"},{"issue":"1","key":"359_CR34","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ajpath.2012.03.022","volume":"181","author":"T Hisatomi","year":"2012","unstructured":"Hisatomi T, Nakao S, Murakami Y, Noda K, Nakazawa T, Notomi S, et al. The regulatory roles of apoptosis-inducing factor in the formation and regression processes of ocular neovascularization. Am J Pathol. 2012;181(1):53\u201361.","journal-title":"Am J Pathol"},{"key":"359_CR35","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.drup.2015.06.001","volume":"21-22","author":"K Selvaraju","year":"2015","unstructured":"Selvaraju K, Mazurkiewicz M, Wang X, Gullbo J, Linder S, D\u2019Arcy P. Inhibition of proteasome deubiquitinase activity: a strategy to overcome resistance to conventional proteasome inhibitors? Drug Resist Updat. 2015;21-22:20\u20139.","journal-title":"Drug Resist Updat"},{"key":"359_CR36","doi-asserted-by":"crossref","first-page":"e10510","DOI":"10.7554\/eLife.10510","volume":"4","author":"D Xu","year":"2015","unstructured":"Xu D, Shan B, Lee BH, Zhu K, Zhang T, Sun H, et al. Phosphorylation and activation of ubiquitin-specific protease-14 by Akt regulates the ubiquitin-proteasome system. Elife. 2015;4:e10510.","journal-title":"Elife"},{"issue":"19","key":"359_CR37","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1093\/hmg\/ddi312","volume":"14","author":"V Menendez-Benito","year":"2005","unstructured":"Menendez-Benito V, Verhoef LG, Masucci MG, Dantuma NP. Endoplasmic reticulum stress compromises the ubiquitin-proteasome system. Hum Mol Genet. 2005;14(19):2787\u201399.","journal-title":"Hum Mol Genet"},{"issue":"3","key":"359_CR38","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1182\/blood.V86.3.1148.1148","volume":"86","author":"A Bedi","year":"1995","unstructured":"Bedi A, Barber JP, Bedi GC, El-Deiry WS, Sidransky D, Vala MS, et al. BCR-ABL-mediated inhibition of apoptosis with delay of G2\/M transition after DNA damage: a mechanism of resistance to multiple anticancer agents. Blood. 1995;86(3):1148\u201358.","journal-title":"Blood"},{"issue":"5","key":"359_CR39","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/sj.cdd.4401210","volume":"10","author":"AE Bueno-da-Silva","year":"2003","unstructured":"Bueno-da-Silva AE, Brumatti G, Russo FO, Green DR, Amarante-Mendes GP. Bcr-Abl-mediated resistance to apoptosis is independent of constant tyrosine-kinase activity. Cell Death Differ. 2003;10(5):592\u20138.","journal-title":"Cell Death Differ"},{"issue":"19","key":"359_CR40","doi-asserted-by":"crossref","first-page":"9118","DOI":"10.18632\/oncotarget.2361","volume":"5","author":"X Chen","year":"2014","unstructured":"Chen X, Shi X, Zhao C, Li X, Lan X, Liu S, et al. Anti-rheumatic agent auranofin induced apoptosis in chronic myeloid leukemia cells resistant to imatinib through both Bcr\/Abl-dependent and -independent mechanisms. Oncotarget. 2014;5(19):9118\u201332.","journal-title":"Oncotarget"},{"issue":"3","key":"359_CR41","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.18632\/oncotarget.6425","volume":"7","author":"H Huang","year":"2016","unstructured":"Huang H, Liao Y, Liu N, Hua X, Cai J, Yang C, et al. Two clinical drugs deubiquitinase inhibitor auranofin and aldehyde dehydrogenase inhibitor disulfiram trigger synergistic anti-tumor effects in vitro and in vivo. Oncotarget. 2016;7(3):2796\u2013808.","journal-title":"Oncotarget"},{"issue":"1","key":"359_CR42","doi-asserted-by":"crossref","first-page":"57","DOI":"10.4161\/auto.3424","volume":"3","author":"E Corcelle","year":"2007","unstructured":"Corcelle E, Djerbi N, Mari M, Nebout M, Fiorini C, Fenichel P, et al. Control of the autophagy maturation step by the MAPK ERK and p38: lessons from environmental carcinogens. Autophagy. 2007;3(1):57\u20139.","journal-title":"Autophagy"},{"key":"359_CR43","doi-asserted-by":"crossref","first-page":"e1510","DOI":"10.1038\/cddis.2014.468","volume":"5","author":"C Kao","year":"2014","unstructured":"Kao C, Chao A, Tsai CL, Chuang WC, Huang WP, Chen GC, et al. Bortezomib enhances cancer cell death by blocking the autophagic flux through stimulating ERK phosphorylation. Cell Death Dis. 2014;5:e1510.","journal-title":"Cell Death Dis"}],"container-title":["Journal of Hematology & Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-016-0359-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,27]],"date-time":"2020-09-27T13:57:48Z","timestamp":1601215068000},"score":1,"resource":{"primary":{"URL":"http:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-016-0359-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,25]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["359"],"URL":"https:\/\/doi.org\/10.1186\/s13045-016-0359-x","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,25]]},"article-number":"129"}}